Powered By
Hi Rosalind,
I was curious so I researched the decision . Your doctor is using standards of care based on your dx. Monitoring using state of the art methods would be my goal.
Here is the info:
Yes, your oncologist's plan to forego maintenance medications after completing chemotherapy for stage 1c1 mucinous tumor of low malignant potential (LMP/borderline tumor) aligns with standard oncologic guidelines
.✅ Understanding Your Treatment PlanStage 1C1 Definition: Means the tumor capsule ruptured during surgical removal (surgical spill).
LMP/Borderline Nature: These tumors have low malignant potential, meaning they are non-invasive and grow slowly.
No Maintenance Standard: Adjuvant maintenance therapies (like targeted drugs or continuous chemo) are not standard or proven beneficial for early-stage LMP tumors after primary treatment.
Surveillance Focus: Care shifts completely to active monitoring and regular physical exams or imaging rather than active medication.📊
Recommended Post-Treatment Steps
Routine Imaging: Periodic pelvic ultrasounds or scans as ordered by your specialist.
Blood Markers: Monitoring tumor markers like CA-125 if they were elevated initially.
Long-Term Follow-Up: Consistent clinical visits, since borderline tumors can occasionally recur years later.
Appendix Check: Ensuring your medical history cleared or evaluated the appendix, which is standard for mucinous subtypes.
Hope this helps, especially monitoring the appendix.
Sending hugs, Kaye🥰
That's a great question to think critically about! Maintenance therapy decisions are highly individualized, and your oncologist's recommendation is based on several factors specific to your situation.
Maintenance therapy is generally considered for people with advanced ovarian cancer, particularly those at higher risk of Show Full Answer
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
